Oral Isotretinoin in The Treatment of Melasma A Randomized Controlled Clinical Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

Melasma is a common refractory acquired hyperpigmentation of the skin having a serious impact on patients' quality of life. Melasma is challenging to treat. Treatment is often a multimodality approach. Due to the attached psychological and social stress, it is important to counsel patients with melasma adequately about the chronicity of the disease, the importance of photoprotection, and the role of hormones in disease persistence before embarking on therapeutic correction. So in this study, we are exploring the efficacy of oral isotretinoin for treating melasma.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: f
View:

• Age between 18 and 50 years

• Patients complaining of melasma.

• Patients with all types of melasma (epidermal, dermal and mixed)

• Sexually active women who is willing to follow at least 2 types of contraceptive methods during study period

• Patients with skin type I-V

Locations
Other Locations
Egypt
Dermatology department, Zagazig University Hospitals, Faculty of Medicine, Zagazig University
RECRUITING
Zagazig
Contact Information
Primary
Hagar Nofal, Dr.
hagarnofal@aucegypt.edu
+201006387707
Time Frame
Start Date: 2023-03-01
Estimated Completion Date: 2024-05-31
Participants
Target number of participants: 40
Treatments
Experimental: Isotretinoin
patients will receive oral isotretinoin (1 mg/kg/day) for 3 months
Active_comparator: Kligman Formula arm
patients will receive topical triple combination formula at night everyday over the affected areas for 3 months
Related Therapeutic Areas
Sponsors
Leads: Zagazig University

This content was sourced from clinicaltrials.gov